Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040024/S146

Restylane Lyft with Lidocaine

Q-Med AB · Decision date Dec 23, 2025

FDA DECISIONP040024/S146

What did the FDA approve?

FDA records P040024/S146 as a supplement to PMA P040024, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Dec 23, 2025.

FDA approval order statement

Approval for the postapproval study (PAS) protocol submitted to comply with the conditions of approval outlined in the approval order for P040024/S142.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
General, Plastic Surgery
Decision date
Dec 23, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P040024/S146
Regulatory pathway
PMA supplement
Applicant
Q-Med AB
Product code
LMH
Decision code
APPR
Decision date
Dec 23, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Applicant
Q-Med AB
Product code
LMH
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P040024/S144 · Related supplement

    Restylane Injectable Gel

  2. P040024/S142 · Related supplement

    Restylane Lyft with Lidocaine

  3. P040024/S146 received

    Application receipt date recorded by FDA.

  4. P040024/S146 · FDA decision

    Normal 180 Day Track No User Fee

  5. P040024/S143 · Related supplement

    Restylane-L 1 mL; Restylane Lyft with Lidocaine 1 mL; Restylane Eyelight 0.5 mL

  6. P040024/S147 · Related supplement

    Restylane Lyft with Lidocaine

  7. P040024/S148 · Related supplement

    RESTYLANE INJECTABLE GEL

Timeline entries are records held by MedtechLedger for P040024. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040024

Product / regulatory recordCompanyPathwayDecision dateSource
Q-Med ABPMA supplementSep 26, 2025FDA
Q-Med ABPMA supplementNov 4, 2025FDA
Q-Med ABPMA supplementJan 29, 2026FDA
Q-Med ABPMA supplementFeb 5, 2026FDA
Q-Med ABPMA supplementMar 12, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Q-Med AB

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Seminariegatan 21, Uppsala, SE-752-28

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records